ducovest

XLV:ARCA-SPDR Select Sector Fund - Health Care (USD)

ETF | Health | NYSE Arca

Last Closing

USD 147.71

Change

+1.94 (+1.33)%

Market Cap

USD 13.53B

Volume

8.79M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

The investment seeks investment results that, before expenses, correspond generally to the price and yield performance of publicly traded equity securities of companies in the Health Care Select Sector Index. In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies from the following industries: pharmaceuticals; health care equipment & supplies; health care providers & services; biotechnology; life sciences tools & services; and health care technology. The fund is non-diversified.

Company Website : www.spdrs.com

Currency: USD

Country : USA

Inception Date: 16/12/1998

Primary Benchmark: S&P Health Care Select Sector TR USD

Primary Index: MSCI ACWI NR USD

Gross Expense Ratio: 0.15%

Management Expense Ratio: 0.13 %

Unadjusted Closing Price

Adjusted Closing Price

Assets

N/A

Top Holdings

N/A

Top Sectors

N/A

Top Regions

N/A

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-03-27 )

Largest Industry Peers for Health

Symbol Name Mer Price(Change) Market Cap
VHT Vanguard Health Care Index Fun.. 0.10 %

N/A

 USD 16.98B
XBI SPDR® S&P Biotech ETF 0.35 %

N/A

 USD 7.05B
IHI iShares U.S. Medical Devices E.. 0.43 %

N/A

 USD 5.55B
IXJ iShares Global Healthcare ETF 0.46 %

N/A

 USD 4.11B
IYH iShares U.S. Healthcare ETF 0.43 %

N/A

 USD 3.23B
FHLC Fidelity® MSCI Health Care In.. 0.08 %

N/A

 USD 2.94B
FXH First Trust Health Care AlphaD.. 0.63 %

N/A

 USD 1.33B
FBT First Trust NYSE Arca Biotechn.. 0.57 %

N/A

 USD 1.08B
IHF iShares U.S. Healthcare Provid.. 0.43 %

N/A

 USD 0.82B
IHE iShares U.S. Pharmaceuticals E.. 0.42 %

N/A

 USD 0.69B

ETFs Containing XLV

HYLG Global X Funds - Global X.. 54.59 % 0.00 %

N/A

 USD 2.85M
PRAE Northern Lights Fund Trus.. 22.45 % 0.00 %

N/A

 USD 5.59M
TACK Fairlead Tactical Sector .. 12.39 % 0.00 %

N/A

 USD 0.21B
XLSR SPDR® SSGA U.S. Sector R.. 10.90 % 0.00 %

N/A

 USD 0.50B
AESR 10.35 % 0.00 %

N/A

 N/A
THLV THOR Financial Technologi.. 9.70 % 0.00 %

N/A

 USD 0.05B
SSUS Day Hagan/Ned Davis Resea.. 9.24 % 0.00 %

N/A

 USD 0.61B
LCR Leuthold Core ETF 4.10 % 0.00 %

N/A

 USD 0.08B
FUT:CA 0.00 % 0.81 %

N/A

 N/A
QGTA 0.00 % 0.37 %

N/A

 N/A
QLS 0.00 % 0.76 %

N/A

 N/A
USHG 0.00 % 0.00 %

N/A

 N/A
QPX AdvisorShares Q Dynamic G.. 0.00 % 0.00 %

N/A

 USD 0.02B
TDSB Cabana Target Drawdown 7 .. 0.00 % 0.00 %

N/A

 USD 0.12B
FATT 0.00 % 0.00 %

N/A

 N/A
RSPY 0.00 % 0.00 %

N/A

 N/A
RRH 0.00 % 0.00 %

N/A

 N/A

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange (NYSE Arca)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 8.31% 86% B+ 71% C-
Dividend Return 0.38% 85% B 23% F
Total Return 8.69% 91% A- 71% C-
Trailing 12 Months  
Capital Gain 15.94% 82% B 63% D
Dividend Return 1.73% 100% F 24% F
Total Return 17.67% 82% B 60% D-
Trailing 5 Years  
Capital Gain 60.99% 95% A 75% C
Dividend Return 8.22% 95% A 29% F
Total Return 69.21% 100% F 74% C
Average Annual (5 Year Horizon)  
Capital Gain 9.83% 86% B+ 72% C
Dividend Return 11.07% 95% A 71% C-
Total Return 1.23% 90% A- 31% F
Risk Return Profile  
Volatility (Standard Deviation) 10.81% 91% A- 79% B-
Risk Adjusted Return 102.39% 100% F 99% N/A
Market Capitalization 13.53B 100% F 94% A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

High dividend returns

The stock has outperformed its sector peers on average annual dividend returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile. This can be a good buy, especially if it is outperforming on total return basis , for investors seeking high income yields.

Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:

There is nothing we particularly dislike